Treatment of Pichia Species Infections
For invasive Pichia infections (including bloodstream infections), an echinocandin is the recommended first-line therapy, with amphotericin B formulations as alternatives for resistant or refractory cases.
Initial Therapy Approach
The treatment of Pichia species infections should follow the same principles as invasive candidiasis, as Pichia species (particularly Pichia kudriavzevii, formerly Candida krusei) are closely related yeasts with similar pathogenic potential 1.
First-Line Treatment for Invasive Disease
Echinocandins are the preferred initial therapy:
- Caspofungin: 70 mg loading dose, then 50 mg daily
- Micafungin: 100 mg daily
- Anidulafungin: 200 mg loading dose, then 100 mg daily
This recommendation is based on strong evidence for candidemia management 1. A case report specifically demonstrated successful treatment of Millerozyma farinosa (formerly Pichia farinosa) catheter-related bloodstream infection with micafungin 2.
Alternative Agents
Amphotericin B formulations are critical alternatives, particularly for:
- Azole-resistant isolates (Pichia kudriavzevii has intrinsic fluconazole resistance) 3
- Echinocandin-resistant or refractory infections
- Lipid formulation amphotericin B: 3-5 mg/kg daily 1
- Amphotericin B deoxycholate: 0.3-1 mg/kg daily (depending on infection site)
Critical Management Considerations
Source Control is Mandatory
- Remove central venous catheters as early as safely possible 1, 2
- Drain abscesses or infected fluid collections
- Address any anatomical abnormalities or foreign bodies
Antifungal Susceptibility Testing
Always obtain susceptibility testing for Pichia isolates 1. Key points:
- Pichia kudriavzevii (formerly C. krusei) has intrinsic fluconazole resistance 3
- Increasing voriconazole resistance reported (9.4% in recent data) 3
- Non-wild-type phenotypes to amphotericin B and posaconazole occur in ~40% of isolates 3
- Multi-drug resistance is emerging (15.3% resistant to ≥2 antifungal classes) 3
Site-Specific Treatment Modifications
For CNS infections:
- Amphotericin B deoxycholate 1 mg/kg IV daily, OR
- Liposomal amphotericin B 5 mg/kg daily
- Consider adding flucytosine 25 mg/kg four times daily for salvage therapy 1
- Remove infected CNS devices (shunts, drains) whenever possible 1
For ocular infections (keratitis):
- Topical amphotericin B AND natamycin
- Systemic itraconazole as adjunctive therapy 4
For urinary tract infections:
- Fluconazole 200-400 mg daily for susceptible isolates only
- For resistant species: Amphotericin B deoxycholate 0.3-0.6 mg/kg daily 1
- Remove urinary catheters whenever feasible 1
For superficial infections (onychomycosis):
- Itraconazole in standard courses 5
Duration of Therapy
- Minimum 2 weeks after documented bloodstream clearance and resolution of symptoms 1
- Obtain daily or every-other-day blood cultures until clearance is documented 1
- Continue therapy until all clinical, laboratory, and radiological abnormalities resolve for deep-seated infections 1
Common Pitfalls to Avoid
Do NOT use fluconazole empirically for suspected Pichia infections—intrinsic resistance is common, particularly with P. kudriavzevii 3
Do NOT delay catheter removal—this is associated with treatment failure and increased mortality 1, 2
Do NOT assume antifungal susceptibility—resistance patterns are evolving rapidly, with increasing multi-drug resistance 3
Perform ophthalmologic examination within the first week for all patients with Pichia bloodstream infections to detect endophthalmitis 1
Image for metastatic foci (abdominal CT/ultrasound) if blood cultures remain persistently positive 1
Special Populations
Neutropenic patients:
- Echinocandins remain first-line 1
- Perform dilated funduscopic exam within first week after neutrophil recovery 1
Neonates:
- Amphotericin B deoxycholate 1 mg/kg daily is preferred 1
- Echinocandins should be reserved for salvage therapy 1
The emergence of multi-drug resistant Pichia species, particularly P. kudriavzevii, necessitates aggressive initial therapy with echinocandins, prompt source control, and mandatory susceptibility testing to guide definitive therapy 3.